Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide-Reference-Cited by-同舟云学术

Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide

Published:2021-03-08 Issue:4 Volume:14 Page:503-512
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Guo Meihua¹^ORCID,Zhou Jin²,Fan Shengjin³,Li Limin²,Chen Hongzhu¹,Lin Liwang¹,Zhao Qilei¹,Wang Xinyu¹,Liu Wensheng¹,Wu Zhiqiang¹,Hai Xin¹

Affiliation:

1. Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, China

2. Department of Hematology, Southern University of Science and Technology Hospital, Shenzhen, China

3. Department of Hematology, First Affiliated Hospital of Harbin Medical University, Harbin, China

Funder

National Natural Science Foundation of China

Foundation of First Affiliated Hospital of Harbin Medical University

Foundation of Health Commission of Heilongjiang Province

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2021.1893940

Reference30 articles.

1. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

2. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription

3. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action

4. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress on arsenic, arsenic-containing medicinal materials, and arsenic-containing preparations: clinical application, pharmacological effects, and toxicity;Frontiers in Pharmacology;2024-03-01

2. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients;Biomedicine & Pharmacotherapy;2023-07

3. Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients;Environmental Toxicology and Pharmacology;2023-06

4. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia;Cancer Chemotherapy and Pharmacology;2022-06-27

5. Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients;Frontiers in Oncology;2022-05-12